TickerRMTG
SectorBiotechnology
Mkt cap$384K
EV / EBITDAN/A
PostureHigh Velocity
Composite62/100
LensTarget-side

SE-Cluster Research·Issuer Brief·Q2 2026CIK 1760026

Regenerative Medical Technology Group Inc.

RMTGHIGH VELOCITYFILING INTENSITY

Regenerative Medical Technology Group Inc. reads as High Velocity (composite 62/100); pressure / disclosure signals dominate the posture this cycle · primary market Healthcare.

Lens

Disclosed M&A capital (2023–2025)

N/A

−99%

vs N/A in 2020–2022

Disclosed transactions

N/A

flat

0/3 active fiscal years in window

Buyer archetype

Selective Buyer

Acquisition use is visible but targeted.

Composite score

/100

High Velocity dominates · Filing Intensity

Financial snapshotRevenue$5M
EBITDAN/A
Enterprise value$18M
EV / Revenue3.5×
EV / EBITDAN/A
P/EN/A
Cash$1M
Total debtN/A
as of 2026-05-10

§ I·SE-Cluster Issuer Brief

Behavioral posture, nine reads.

Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.

Active Acquirer

6/100

Companies actively deploying disclosed capital into M&A

$4M disclosed buyer spend

Buyer Cadence

16/100

Buyer-side companies with recent filing activity

20 8-Ks

Target Probability

0/100

Issuers showing target-side patterns from filings

Spin/Carve

0/100

Issuers showing spin-off, carve-out, or sum-of-parts posture

Pressure Watch

10/100

Issuers facing activism, governance, or control pressure

Distress Watch

37/100

Issuers showing financial-distress filing patterns

10-Q 203d stale
10-K 421d stale

Restatement Risk

0/100

Issuers with accounting-integrity flags from filings

Capital Velocity

Dominant

62/100

Issuers with the highest filing-activity intensity

20 8-Ks
3 form types

Quiet Power

0/100

Large issuers with low signal volume and clean disclosure cadence

Enterprise value $18M
10-Q 203d ago
1 active signals

§ II·SE-Cluster Issuer Brief

Capital cadence.

Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.

Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $4M · Peak count: 1

FY	Disclosed buys	Disclosed spend	Avg ticket	Audited tier
2025	N/A	N/A	N/A	N/A
2024	N/A	N/A	N/A	N/A
2023	N/A	N/A	N/A	N/A
2022	N/A	N/A	N/A	N/A
2021	N/A	$200K	N/A	N/A
2020	N/A	N/A	N/A	N/A

§ III·SE-Cluster Issuer Brief

Strategy posture.

The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.

Archetype mix

Geographic Expansion
25%
Tuck In
25%
Bolt On
25%
Technology Acquisition
25%

Strategy keywords

Terms recurring across recent 10-K acquisition disclosures.

geographic_expansion
tuck_in
bolt_on
technology_acquisition

§ IV·SE-Cluster Issuer Brief

Filing language.

Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.

“Our acquisition strategy focuses on targets that offer clear synergies with our existing operations, have compatible corporate cultures, and can be integrated efficiently into our operational structure”

10-KFY2025

“we continue to evaluate strategic acquisition opportunities that could accelerate our growth in key markets or enhance our technological capabilities”

10-KFY2025

“Possible future acquisitions include websites / social media pages, in addition to physical numismatic businesses that could become available.”

10-KFY2022

“The Company anticipates organic growth as well growth through acquisitions, as the right opportunities present themselves.”

10-KFY2022

§ V·SE-Cluster Issuer Brief

Market context.

Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.

Primary market

Healthcare

Market spend (2023–2025): $195B
Market spend (2020–2022): $253.6B
Recent vs prior: −23%
Issuer rank in market: N/A
Share of market capital: 0.0%

Valuation positioning

N/AEV / EBITDA

RMTG trades at a -53.7-turn discount to the Healthcare peer median of 12.9×.

EV / Revenue: 3.5×
Net debt / EBITDA: N/A
Peer median EV / EBITDA: 12.9×

Trading comparables

FMP market data · 2026-05-10

Company	EV / EBITDA	EV / Rev	Net debt / EBITDA	Revenue	M&A 2023–2025
AbbVie Inc.ABBV	23.4×	6.7×	3.1×	$62.8B	$18B
UnitedHealth Group IncorporatedUNH	17.2×	0.9×	1.9×	$449.7B	$28.1B
Amgen Inc.AMGN	12.9×	6.0×	2.6×	$37.2B	$26.7B
Elevance Health, Inc.ELV	11.7×	0.5×	2.5×	$200.4B	$6.4B
HCA Healthcare, Inc.HCA	9.3×	1.9×	2.8×	$76.4B	$1.3B

Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Healthcare. Bars scaled to the highest EV/EBITDA in the set.

§ VI·SE-Cluster Issuer Brief

Buyer landscape.

Public buyers whose stated archetypes, target categories, and recent cadence align with this issuer as a plausible acquisition target. Scores cross EDGAR signal and disclosure overlap.

Likely buyers

No public buyers surface as a strong target-side fit on current signal.

Likely sellers / divestiture partners

No reciprocal divestiture / strategic-alternatives matches identified.

§ VII·SE-Cluster Issuer Brief

Filing activity & signal stream.

Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.

Filing cadence

10-K (annual)72025-04-15
10-Q (quarterly)212025-11-19
8-K (event)202025-05-21
Proxy / DEF 14A0N/A
Activism (13D / DFAN / PREC)0N/A

Signals on file

info
Signal
10-K strategy themes

§ VIII·SE-Cluster Issuer Brief

Audited corpus.

No audited record on file for this CIK in the current v6 corpus.

This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.

Search